Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Credit: Novo Nordisk. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial. Semaglutide reduced the risk of kidney disease worsening, renal failure ...

Credit: Novo Nordisk. The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial. Semaglutide reduced the risk of kidney disease worsening, renal failure, and CV ...

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Semaglutide lowered the risk for kidney disease events by 24% in the FLOW trial. The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney ...

The approval was based on data from the randomized, double-blind, placebo-controlled FLOW trial (ClinicalTrials.gov Identifier: NCT03819153), which evaluated the effects of semaglutide ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

The trial achieved its primary endpoint with semaglutide 1 mg ... the risk of major kidney and cardiovascular outcomes,” said FLOW trial co-chair Richard E. Pratley, MD, medical director ...